» Articles » PMID: 32092974

New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies

Overview
Journal J Clin Med
Specialty General Medicine
Date 2020 Feb 26
PMID 32092974
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

In metastatic renal cell carcinoma (mRCC) the PD-1 immune-checkpoint inhibitor (ICI) Nivolumab became a standard second line treatment option in 2015 based on a significant improvement of overall survival compared to Everolimus. Current pivotal phase 3 studies showed that PD-1 ICI-based combinations were more efficacious than the VEGFR-TKI Sunitinib, a previous standard of care, leading to approval of three new regimens as guideline-recommended first-line treatment. Nivolumab plus Ipilimumab is characterized by a survival advantage, a high rate of complete response and durable remissions in intermediate and poor prognosis patients. Despite frequent immune-mediated side effects, fewer symptoms and a better quality of life were observed compared to Sunitinib. Pembrolizumab or Avelumab plus Axitinib were characterized by an improved progression-free-survival and a high response rate with a low rate of intrinsic resistance. In addition, Pembrolizumab plus Axitinib reached a significant survival benefit. The side effect profile is driven by the chronic toxicity of Axitinib, but there is additional risk of immune-mediated side effects of the PD-1/PD-L1 ICIs. The quality of life data published so far do not suggest any improvement regarding patient-reported outcomes compared to the previous standard Sunitinib. The PD-1/PD-L1 ICIs thus form the backbone of the first-line therapy of mRCC.

Citing Articles

Anti-hypertensives associated with survival in cancer patients receiving immunotherapy: new evidence from a real-world cohort study and meta-analysis.

Ma P, Zhang Z, Qian M, Jiang H, Zhao Y, Shan Q Ther Adv Med Oncol. 2024; 16:17588359241292227.

PMID: 39529892 PMC: 11552054. DOI: 10.1177/17588359241292227.


Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.

Hilser T, Darr C, Niegisch G, Schnabel M, Foller S, Hauser L Cancers (Basel). 2024; 16(17).

PMID: 39272856 PMC: 11393955. DOI: 10.3390/cancers16172998.


Small Bowel Perforation Due to Renal Carcinoma Metastasis: A Comprehensive Case Study and Literature Review.

Todorovic D, Stojanovic B, Filip M, dordevic D, Stankovic M, Jovanovic I Diagnostics (Basel). 2024; 14(7).

PMID: 38611674 PMC: 11011689. DOI: 10.3390/diagnostics14070761.


Cancer associated macrophage-like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time.

Ali A, Adams D, Kasabwala D, Tang C, Ho T Sci Rep. 2023; 13(1):10544.

PMID: 37386095 PMC: 10310728. DOI: 10.1038/s41598-023-37671-3.


Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer.

Ma X, Fang W, Wang D, Shao N, Chen J, Nie T Pharmaceutics. 2023; 15(4).

PMID: 37111692 PMC: 10145863. DOI: 10.3390/pharmaceutics15041207.


References
1.
Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

2.
Choueiri T, Halabi S, Sanford B, Hahn O, Michaelson M, Walsh M . Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017; 35(6):591-597. PMC: 5455807. DOI: 10.1200/JCO.2016.70.7398. View

3.
Choueiri T, Hessel C, Halabi S, Sanford B, Michaelson M, Hahn O . Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018; 94:115-125. PMC: 6057479. DOI: 10.1016/j.ejca.2018.02.012. View

4.
Cella D, Grunwald V, Escudier B, Hammers H, George S, Nathan P . Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019; 20(2):297-310. PMC: 6701190. DOI: 10.1016/S1470-2045(18)30778-2. View

5.
Rini B, Plimack E, Stus V, Gafanov R, Hawkins R, Nosov D . Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1116-1127. DOI: 10.1056/NEJMoa1816714. View